samedan logo
 
 
 
spacer
home > pmps > summer 2003 > responding to nasal and pulmonary drug delivery trends
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Responding to Nasal and Pulmonary Drug Delivery Trends

The importance of the implementation of drug delivery technologies into new drug products has risen considerably in recent years. The drug delivery industry is experiencing a growth rate of around 15 per cent per year, which is about double the growth of the overall pharmaceutical industry.

Various reasons, ranging from innovative technology to pharmacoeconomic issues, are contributing to the success of the drug delivery industry. In particular the administration of drug products via the nasal and pulmonary route offers the opportunity to open a new market.

The actual patient's position on these mucosal administration routes is increasingly important. It has to be realised that new drug delivery technologies can be successful in the market only as long as they are accepted by the patients themselves.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr René Bommer, Director Business Development at Ing E Pfeiffer GmbH

René Bommer is Business Development Director at Pfeiffer's Pharmaceutical Division. Following a PhD in Chemistry, Renй Bommer was a Researcher at Scripps Clinic in La Jolly, USA, and at Altana Pharma in Germany.

After a lectureship at the University of Buenos Aires in Argentina, René joined Pfeiffer.

spacer
Dr René Bommer
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

ERT and Science 37 Partner to Deliver High-Quality Data during Virtual Trials

ERT, the global leader in clinical endpoint data collection and Science 37, the leader in decentralized clinical trials, today announced a partnership enabling ERT’s Cardiac Safety, Respiratory, and Imaging solutions to be incorporated into the Science 37 virtual, or decentralized clinical trial offering. The combined solution significantly improves data quality while dramatically reducing patient burden.
More info >>

White Papers

Smaller, Smarter, Electronic, Connected: The Next Generation of Drug-Delivery Devices

Phillips-Medisize

An exciting trend in drug delivery is underway: the movement toward smaller, smarter, wirelessly connected electronic devices that allow patient-administered therapy. Inspired by the technological advancements driving the consumer electronics market, new methods for drug delivery show great promise for all stakeholders. Patients wishing to claim more autonomy over their drug regimens, caregivers and medical professionals wanting to more closely monitor drug compliance, health insurance organizations looking to keep costs down, and developers of pharmaceutical products interested in conducting better managed clinical trials can all benefit from these novel, next-generation technologies.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement